International Journal of Hematology and Oncology 2020, Vol 30, Num 2 Page(s): 079-086
RESULTS OF FIRST LINE TREATMENT IN HODGKIN'S DISEASE: SINGLE CENTER EXPERIENCE

FEVZİ ALTUNTAŞ1, BÜLENT ESER1, BÜNYAMİN KAPLAN1, ÖZLEM CANÖZ1, KÜRŞAT GÜNDOĞAN1, METİN ÖZKAN1, ÖZLEM ER1, H ŞENOL ÇOŞKUN1, MUSTAFA ÇETİN1, ERAY KARAHACIOĞLU1, ALİ ÜNAL1

Erciyes Üniversitesi Tıp Fakültesi, Dedeman Hastanesi, Hematoloji-Onkoloji BD, KAYSERİ

Keywords: adult hodgkin's disease, clinicopathological features, chemotherapy, radiotherapy
Hodgkin's disease (HD) is a curable malignancy that could be treated with combination chemotherapy regimens and/or radiation therapy. One hundred sity one HD cases followed in our institute between 1989 and 2002 were evaluated, retrospectively. One hundred eight (67%) of the patients were male and 53 (33%) female. The patients' age ranged from 15 to 80 years with a median age of 45 years. According to Rye classification frequency of histologic subtypes was as follows: 19.9% lymphocyte predominant, 23% nodular sclerosis, 47.8% mixed cellularity, and 9.3% lymphocyte depletion. Of the patients 14% was stage I, 25% stage II, 39% stage III, and 22% stage IV. Cyclophosphamide, vincristine, procarbazine and prednisolone (COPP); Adriamycin, bleomycin, vinblastine and dacarbazine (ABVD); COPP/ABVD alterne; COPP/ABV hybrid regimens and radiation therapy were used as first line therapy in 48.4%, 23%, 10%, 6.2% and 12.4% of patients, respectively. Complete remission was achieved in 83.2%, and partial remission in 7.5% of the patients; response could not be obtained in remaining 9.3% of the patients. Disease progression or recurrence was observed in 30.4% of the patients. Five-year overall survival (OS) and disease-free survival (DFS) rate were found as 82.6% and 61.6 % of all patients, respectively. Clinical outcome of the ABVD regimen was superior to others. The high complete remission rate (81%), long-term OS (100%) and DFS (88.3%) were obtained with these regimen. Our results showed that Hodgkin's disease is a curable malignancy and ABVD is the best regimen for the first line treatment.